$NMRA News

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Neumora Therapeutics Q1 EPS $(0.30) Beats $(0.33) Estimate

Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary

Guggenheim Reiterates Buy on Neumora Therapeutics, Maintains $14 Price Target

Needham Reiterates Buy on Neumora Therapeutics, Maintains $8 Price Target

Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ...

Neumora Therapeutics: Downgrading After Navacaprant Development Setback

Neumora Therapeutics Q4 Earnings Call Highlights

Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript

Neumora Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Neumora Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.

Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Neumora Therapeutics Q4 EPS $(0.35) Misses $(0.33) Estimate

Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity

Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511